Level of FABP3, FABP4, Nt-proBNP and Total Cardiovascular Risk in the Population of Central Kazakhstan

Alexandr Borisovich Marchenko; Farida Ustarovna Nildibayeva; Marina Anatolevna Sorokina; Elena Mihaylovna Laryushina; Lyudmila Gennadevna Turgunova; Anar Akyilbekovna Turmukhambetova

doi:10.3889/oamjms.2017.021

Authors

Alexandr Borisovich Marchenko Karaganda State Medical University, Department of Internal Medicine 2, Karaganda
Farida Ustarovna Nildibayeva Karaganda State Medical University, Department of Internal Medicine 2, Karaganda
Marina Anatolevna Sorokina Karaganda State Medical University, Department of Medical Biophysics and Informatics, Karaganda
Elena Mihaylovna Laryushina Karaganda State Medical University, Department of Internal Medicine 2, Karaganda
Lyudmila Gennadevna Turgunova Karaganda State Medical University, Department of Internal Medicine 3, Karaganda
Anar Akyilbekovna Turmukhambetova Karaganda State Medical University, Vice-rector for strategic development, research and international collaboration, Karaganda

DOI:

https://doi.org/10.3889/oamjms.2017.021

Keywords:

cardiac markers, total cardiovascular risk, epidemiology, pathogenesis, Central Kazakhstan

Abstract

AIM: The study analyzed the level of cytokines playing the significant role in the diagnosis of circulatory system diseases and total cardiovascular risk.

MATERIAL AND METHODS: The study involved 1,244 residents of Karaganda region. We had studied baseline participant characteristics, in addition to calculating the total cardiovascular risk and assessment of Fatty Acid Binding Proteins 3 (FABP3), Fatty Acid Binding Proteins 4 (FABP4) and N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) level.

RESULTS: The results showed the combination of high cardiovascular risk (CVR) with increased titers of cardiac markers, reflecting common pathogenic mechanisms in its development, among residents of Karaganda region.

CONCLUSION: The combination of high CVR with the increased titers of cardiac markers showed common pathogenic mechanisms in its development, and support the diagnostic and prognostic value of these parameters among residents of Karaganda region, and also reflects the possibility to include these cardiac markers in the program of screening survey of population for early prevention of cardiovascular disease and its complications.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Moran AE, Roth GA, Narula J, Mensah GA. 1990-2010 global cardiovascular disease atlas. Glob Heart. 2014;9(1): 3-16. https://doi.org/10.1016/j.gheart.2014.03.1220 PMid:25432106 DOI: https://doi.org/10.1016/j.gheart.2014.03.1220

Mendis S, Puska P, Norrving B. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization, 2011: 164.

Banegas JR, Lopez-Garcia E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32(17): 2143-52. https://doi.org/10.1093/eurheartj/ehr080 PMid:21471134 PMCid:PMC3164103 DOI: https://doi.org/10.1093/eurheartj/ehr080

Rodriguez-Artalejo F, Guallar E, Borghi C, et al. Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). BMC Public Health. 2010;10: 382. https://doi.org/10.1186/1471-2458-10-382 PMid:20591142 PMCid:PMC2909167 DOI: https://doi.org/10.1186/1471-2458-10-382

Alihanova KA, Omarkulov BK, Abugalieva TO, Zhakipbekova VA. Izuchenie rasprostranennosti zabolevaniy serdechno-sosudistoy sistemyi sredi naseleniya karagandinskoy oblasti. Fundamentalnyie issledovaniya. 2013;5(9): 804-809.

Kairbekova SZ, Musinov SR, Bayzhunusov EA, i dr. Zdorovye naseleniya Respubliki Kazahstan i deyatelnost organizatsiy zdravoohraneniya v 2012 godu. Statisticheskiy sbornik. Astana. 2013; 105-109.

Zhaksalyikova GB, Bermagambetova GN, Nugumanov TK, i dr. Zdorovye naseleniya Respubliki Kazahstan i deyatelnost organizatsiy zdravoohraneniya v 2015 godu. Statisticheskiy sbornik. Astana. 2016; 17-22.

Conroy RM, PyÃ¶rÃ¤lÃ¤ K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11): 987-1003. https://doi.org/10.1016/S0195-668X(03)00114-3 DOI: https://doi.org/10.1016/S0195-668X(03)00114-3

Sanchez OA, Jacobs Jr, DR, Bahrami H, et al. Increasing aminoterminal-pro-B- type natriuretic peptide precedes the development of arterial hypertension: the multiethnic study of atherosclerosis. J Hypertens. 2015;33(5): 966-74. https://doi.org/10.1097/HJH.0000000000000500 PMid:25909698 PMCid:PMC4410427 DOI: https://doi.org/10.1097/HJH.0000000000000500

Hoefer IE, Steffens S, Ala-Korpela M, et al. Novel methodologies for biomarker discovery in atherosclerosis. Eur Heart J. 2015;36(39): 2635-42. https://doi.org/10.1093/eurheartj/ehv236 PMid:26049157 DOI: https://doi.org/10.1093/eurheartj/ehv236

Bower JK, Lazo M, Matsushita K, et al. N-terminal pro-brain natriuretic peptide (NT-proBNP) and risk of hypertension in the Atherosclerosis Risk in Communities (ARIC) study. American journal of hypertension. 2015;28(10): 1262-1266. https://doi.org/10.1093/ajh/hpv026 PMid:25783741 PMCid:PMC4580540 DOI: https://doi.org/10.1093/ajh/hpv026

Saavedra P, Girona J, Bosquet A, et al. New insights into circulating FABP4: Interaction with cytokeratin 1 on endothelial cell membranes. Biochim Biophys Acta. 2015;1853(11): 2966-74. https://doi.org/10.1016/j.bbamcr.2015.09.002 PMid:26343611 DOI: https://doi.org/10.1016/j.bbamcr.2015.09.002

Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs--mechanisms and therapeutic implications. Nat Rev Endocrinol. 2015;11(10): 592-605. https://doi.org/10.1038/nrendo.2015.122 PMid:26260145 PMCid:PMC4578711 DOI: https://doi.org/10.1038/nrendo.2015.122

Kim Y, Kim SY, Kim Y, Kwon HJ, Kim JR, Lee HK, Yoo KD. Polymorphisms of the heart-type fatty acid-binding protein as a prognostic factor in patients with atherosclerosis. Ann Clin Lab Sci. 2014;44(1):67-72. PMid:24695477

Basar O, Akbal E, Koklu S, et al. Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis. Herz. 2013; 38(4):417-22. https://doi.org/10.1007/s00059-012-3714-x PMid:23324907 DOI: https://doi.org/10.1007/s00059-012-3714-x

Tsukahara R, Haniu H, Matsuda Y, Tsukahara T. Heart-type fatty-acid-binding protein (FABP3) is a lysophosphatidic acid-binding protein in human coronary artery endothelial cells. FEBS Open Bio. 2014;4:947-51. https://doi.org/10.1016/j.fob.2014.10.014 PMid:25426414 PMCid:PMC4239478 DOI: https://doi.org/10.1016/j.fob.2014.10.014

Ishino M, Shishido T, Funayama A, et al. Heart-type fatty acid binding protein as predictor of cardiac mortality and events in patients with acute decompensated heart failure. Circulation. 2010;122(Suppl.21): A14282.

Oremus M, McKelvie R, Don-Wauchope A, et al. A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. Heart failure reviews. 2014;19(4): 413-419. https://doi.org/10.1007/s10741-014-9440-0 PMid:24953975 DOI: https://doi.org/10.1007/s10741-014-9440-0

Ribeiro DG, Silva RP, Barboza DRMM, Lima-JÃºnior RCP, Ribeiro RA, et al. Clinical correlation between N-terminal pro-B-type natriuretic peptide and angiographic coronary atherosclerosis. Clinics. 2014;69(6): 405-12. https://doi.org/10.6061/clinics/2014(06)07 DOI: https://doi.org/10.6061/clinics/2014(06)07

Thumser AE, Moore JB, Plant NJ. Fatty acid binding proteins: tissue-specific functions in health and disease. Current Opinion in Clinical Nutrition & Metabolic Care. 2014;17(2): 124-129. https://doi.org/10.1097/MCO.0000000000000031 PMid:24500438 DOI: https://doi.org/10.1097/MCO.0000000000000031

Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases. Clin Med Insights Cardiol. 2014;8(Suppl. 3): 23-33. PMid:25674026 DOI: https://doi.org/10.4137/CMC.S17067

Hoffmann U, Espeter F, WeiÃŸ C, et al. Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I. BMC Cardiovasc Disord. 2015;15: 50. https://doi.org/10.1186/s12872-015-0026-0 PMid:26072112 PMCid:PMC4488120 DOI: https://doi.org/10.1186/s12872-015-0026-0

Liou K, Ho S, Ooi SY. Heart-type fatty acid binding protein in early diagnosis of myocardial infarction in the era of high-sensitivity troponin: a systematic review and meta-analysis. Ann Clin Biochem. 2015;52(3): 370-81. https://doi.org/10.1177/0004563214553277 PMid:25205855 DOI: https://doi.org/10.1177/0004563214553277

Elmadbouh I, Mahfouz R, Bayomy N, Faried W, Ghanayem N. The value of human heart-type fatty acid binding protein in diagnosis of patients with acute chest pain. The Egyptian Heart Journal. 2012;64(4): 179-184. https://doi.org/10.1016/j.ehj.2012.06.004 DOI: https://doi.org/10.1016/j.ehj.2012.06.004

Dekker MS, Mosterd A, van't Hof AW, Hoes AW. Novel biochemical markers in suspected acute coronary syndrome: systematic review and critical appraisal. Heart. 2010;96(13): 1001-10. https://doi.org/10.1136/hrt.2009.189886 PMid:20584855 DOI: https://doi.org/10.1136/hrt.2009.189886

Komamura K, Sasaki T, Hanatani A, et al. Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy. Heart. 2006;92(5): 615-8. https://doi.org/10.1136/hrt.2004.043067 PMid:16387818 PMCid:PMC1860923 DOI: https://doi.org/10.1136/hrt.2004.043067

Pejovic J, IgnjatoviÄ‡ S, Dajak M, et al. Correlation of N-terminal pro-B-type natriuretic peptide with clinical parameters in patients with hypertension. Vojnosanit Pregl. 2013;70(8): 728-34. https://doi.org/10.2298/VSP110322048P PMid:24069820 DOI: https://doi.org/10.2298/VSP110322048P